Samsung Bioepis reveals new Phase III data on three biosimilars

9 June 2016

South Korean biosiimilars drug developer Samsung Bioepis has announced new data on three of the candidates in its promising biosimilar pipeline at the Annual European Congress on Rheumatology (EULAR 2016).

These candidates include SB5, a biosimilar of the mega-selling arthritis drug Humira (adalimumab), a drug currently marketed by AbbVie (NYSE: ABBV) and the subject of a legal wrangle between the two companies as the US pharma major is seeking to gain new patents and delay the entry of such competitors.

Samsung Bioepis, which was established only in 2012 and is a joint venture between Korean conglomerate Samsung and US biotech Biogen (Nasdaq: BIIB), has announced new data not just on SB5, but on its two other biosimilars in autoimmune disease.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK